We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01301066
First Posted: February 23, 2011
Last Update Posted: April 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Kowa Pharmaceuticals America, Inc.
Eli Lilly and Company
Information provided by (Responsible Party):
Kowa Research Institute, Inc.
February 18, 2011
February 23, 2011
February 10, 2014
April 29, 2014
April 29, 2014
December 2010
March 2013   (Final data collection date for primary outcome measure)
Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks [ Time Frame: 12 weeks minus baseline ]
Percent change of fasting serum low-density lipoprotein cholesterol (LDL-C) at 12 weeks [ Time Frame: 12 Weeks ]
To compare the between-group difference in percent change of fasting serum low-density lipoprotein cholesterol (LDL-C) at 12 weeks in HIV-infected subjects
Complete list of historical versions of study NCT01301066 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Dyslipidemia
  • Drug: Pitavastatin
    Pitavastatin 4 mg QD
    Other Name: Livalo
  • Drug: Pravastatin
    Pravastatin 40 mg QD
  • Experimental: Pitavastatin 4 mg QD
    Intervention: Drug: Pitavastatin
  • Active Comparator: Pravastatin 40 mg QD
    Intervention: Drug: Pravastatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
252
March 2013
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
  • Both men and women of child bearing potential (i.e., not surgically sterile or post-menopausal defined as age >40 years without menses for ≥2 years) must agree to use at least 2 reliable forms of contraception
  • Documented HIV infection.

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Any conditions that may cause secondary dyslipidemia
  • History of coronary artery disease (CAD) or CAD equivalent
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01301066
NK-104-4.05US
No
Not Provided
Not Provided
Kowa Research Institute, Inc.
Kowa Research Institute, Inc.
  • Kowa Pharmaceuticals America, Inc.
  • Eli Lilly and Company
Not Provided
Kowa Research Institute, Inc.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP